8-K: Kairos Pharma Announces 1-for-7 Reverse Stock Split

Kairos Pharma, Ltd. is implementing a 1-for-7 reverse stock split, effective September 1, 2026, to comply with NYSE American listing requirements and potentially improve its market profile.

Summary

• Kairos Pharma, Ltd. announced a 1-for-7 reverse stock split of its common stock, effective September 1, 2026.
• The split aims to increase the per-share trading price and maintain compliance with NYSE American listing standards.
• Every seven shares will be consolidated into one share, with no fractional shares issued; instead, fractional entitlements will be rounded up to the nearest whole share.
• The reverse stock split will proportionally adjust outstanding convertible notes, warrants, and equity awards.
• The company's lead candidate, ENV-105, targets CD105a protein to overcome cancer drug resistance.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative development, primarily driven by the necessity of a reverse stock split to maintain exchange listing, which often signals underlying challenges with share price performance.

Positives

• Aims to maintain compliance with NYSE American listing requirements, preventing potential delisting.
• May improve the company's market profile and attractiveness to institutional investors.
• Fractional shares will be rounded up to the nearest whole share, benefiting small shareholders.
• The company's lead candidate, ENV-105, is designed to combat cancer drug resistance.

Negatives

• A reverse stock split is often a sign of a declining stock price and can be perceived negatively by the market.
• The need for a reverse split suggests the company has not been able to achieve a sufficient share price organically.
• Potential for minor changes in shareholder percentage ownership due to fractional share treatment.

Risks

• The reverse stock split may not achieve its intended effects of increasing the share price or attracting investors.
• Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's success is dependent on the clinical development and potential market approval of its lead candidate, ENV-105.

Future Outlook

The company anticipates that the reverse stock split will reduce the number of outstanding shares, proportionately increase the per-share trading price, and help maintain compliance with NYSE American listing requirements, potentially improving its capital markets profile and ability to attract institutional investors. However, the effectiveness of these outcomes is subject to market conditions and the company's overall performance.

Management Comments

• The Reverse Stock Split is intended to reduce the number of outstanding shares and proportionately increase the per-share trading price and help the Company maintain compliance with the requirements for continued listing on the NYSE American.

Industry Context

StockSavvy.ai notes that reverse stock splits are a common, albeit often viewed negatively, tool for companies, particularly in the biotech sector, to regain compliance with exchange listing rules (e.g., minimum share price requirements). This action by Kairos Pharma is consistent with industry practices for companies facing such challenges, but it does not inherently improve the company's underlying business fundamentals.

Stakeholder Impact

• Shareholders will hold fewer shares, but their proportional ownership interest and voting power remain largely unchanged, except for minor adjustments due to fractional share treatment.
• Holders entitled to fractional shares will receive a whole share, rounding up.
• Warrant holders and equity award recipients will see proportional adjustments to their exercise prices and share counts.

Next Steps

• Shares to begin trading on NYSE American on a split-adjusted basis at market open on September 1, 2026.
• VStock Transfer LLC will notify stockholders of record regarding the Reverse Stock Split.
• Brokers, banks, or other nominees will effect the Reverse Stock Split for beneficial holders.

Key Dates

Recommendation

The reverse stock split is a procedural move to maintain listing, not a fundamental business improvement. While it addresses a compliance issue, it doesn't inherently change the company's value proposition or prospects. Investors should hold and await further clinical or strategic developments.

Keywords

Reverse Stock Split, Biopharmaceutical, Oncology, Drug Resistance, NYSE American, Listing Compliance, ENV-105, Capital Markets